Actelion's Opsumit Shows MERIT In CTEPH

The Switzerland-based biotech Actelion is bullish about new indications and labeling updates for its marketed pulmonary arterial hypertension product macitentan, including in CTEPH, and has also unveiled a promising Phase II candidate for resistant hypertension.